COG AREN1721 - A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Jenna Demedis
Study ID
Protocol Number: 19-1467
More information available at ClinicalTrials.gov: NCT03595124
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers